Joseph Dayan

Dr. Joseph Dayan


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Plastic and Reconstructive Surgery
Verified
Journal Article
Closed access
JDJoseph Dayan
Joseph Dayan
EDErez Dayan
Erez Dayan
MSMark L. Smith
Mark L. Smith
Background: The authors introduce the technique of reverse lymphatic mapping for vascularized lymph node transfer. This physiologic technique allows one to identify which lymph nodes drain the trunk as opposed to the extremity, to minimize the risk of iatrogenic lymphedema. Methods: A prospective study of patients undergoing vascularized lymph node transfer using the reverse lymphatic mapping technique was conducted. Patients received technetium injections in the first and second webspaces of the foot and intradermal indocyanine green injections in the lower abdomen. Lymphatic vessels were traced to the lymph nodes draining the lower abdomen that were harvested; a gamma probe was used to localize lymph nodes draining the lower extremity, which were avoided. In cases of vascularized axillary lymph node transfer, technetium was injected into the hand and indocyanine green was injected into the back and lateral chest. Ten-second counts were recorded of the lymph node flap and the sentinel node draining the extremity for comparison. Results: Thirty-five patients underwent vascularized lymph node transfer (19 groin and 16 axillary lymph node transfers) guided by reverse lymphatic mapping. Follow-up time was 1 to 30 months. Mean 10-second count using the gamma probe for all lymph node flaps was 88.6 (SD, 123; median, 39); mean 10-second count of extremity sentinel nodes was 2462 (SD, 2115; median, 2000). On average, 10-second signal strength of the lymph node flap was 6.0 percent that of the extremity sentinel node. Conclusion: Reverse lymphatic mapping guides vascularized lymph node flap harvest based on physiologic drainage patterns of the trunk and limb that may minimize the risk of iatrogenic lymphedema. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.

4 December 2008 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
SSScott L. Spear
Scott L. Spear
JSJaime Schwartz
Jaime Schwartz
JDJoseph Dayan
Joseph Dayan
MCMark W. Clemens
Mark W. Clemens

29 January 2018 in Annual Review of Medicine
Verified
Journal Article
Closed access
JDJoseph Dayan
Joseph Dayan
CLCatherine Ly
Catherine Ly
RKRaghu P Kataru
Raghu P Kataru
Babak J. MehraraBabak J. Mehrara
Babak J. Mehrara
Lymphedema affects up to 1 in 6 patients who undergo treatment for a solid tumor in the United States. Its prevalence has increased as more effective oncologic therapies have improved patient survival, but there remains no definitive cure. Recent research has elucidated new details in the pathogenesis of the disease and has demonstrated that it is fundamentally an immunologic process that ultimately results in inflammation, fibroadipose deposition, impaired lymphangiogenesis, and dysfunctional lymphatic pumping. These findings have allowed for the development of novel medical and surgical therapies that may potentially alter the standard of care for a disease that has largely been treated by compression. This review seeks to provide an overview of the emerging therapies and how they can be utilized for effective management of lymphedema.

1 May 2017 in Plastic and Reconstructive Surgery
Verified
Journal Article
Closed access
AAAnoushka Afonso
Anoushka Afonso
SOSabine Oskar
Sabine Oskar
KTKay See Tan
Kay See Tan
JDJoseph J. Disa
Joseph J. Disa
BMBabak J. Mehrara
Babak J. Mehrara
JDJoseph Dayan
Joseph Dayan
Background: At present, there are limited data available regarding the use and feasibility of enhanced recovery pathways for patients undergoing microsurgical breast reconstruction. The authors sought to assess patient outcomes before and after the introduction of an enhanced recovery pathway that was adopted at a single cancer center. Methods: A multidisciplinary enhanced recovery pathway was developed for patients undergoing deep inferior epigastric perforator or free transverse rectus abdominis myocutaneous flap breast reconstruction. Core elements of the enhanced recovery pathway included substituting intravenous patient-controlled analgesia with ketorolac and transversus abdominis plane blocks using liposomal bupivacaine, as well as intraoperative goal-directed fluid management. Patients who underwent surgery between April and August of 2015 using the enhanced recovery pathway were compared with a historical control cohort. The primary endpoints were hospital length of stay and total postoperative opioid consumption. Results: In total, 91 consecutive patients were analyzed (enhanced recovery pathway, n = 42; pre–enhanced recovery pathway, n = 49). Mean hospital length of stay was significantly shorter in the enhanced recovery pathway group than in the pre–enhanced recovery pathway group (4.0 days versus 5.0 days; p < 0.0001). Total postoperative morphine equivalent consumption was also lower in the enhanced recovery pathway group (46.0 mg versus 70.5 mg; p = 0.003). There was no difference in the incidence of 30-day complications between the groups (p = 0.6). Conclusion: The adoption of an enhanced recovery pathway for deep inferior epigastric perforator and transverse rectus abdominis myocutaneous flap reconstruction by multiple surgeons significantly decreased opioid consumption and reduced length of stay by 1 day. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

1 January 2009 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
SDSteven P. Davison
Steven P. Davison
JDJoseph Dayan
Joseph Dayan
MCMark W. Clemens
Mark W. Clemens
SSSmitha Sonni
Smitha Sonni
AWAntai Wang
Antai Wang
ACAmy Crane
Amy Crane
Keloids are a common problem with significant recurrence rates despite intralesional steroid treatment and multimodal therapy. The purpose of this study was to evaluate the efficacy of using a 5-fluorouracil (5-FU)/steroid mixture to treat keloids over the past 7 years, comparing the results with use of steroid treatment alone. Patient charts from 1999 to 2006 were reviewed. Patients were stratified into 3 groups: (1) 5-FU/steroid without excision; (2) 5-FU/steroid with excision; and (3) steroid treatment with excision. The percentage of lesion size reduction and symptoms were evaluated. A total of 102 keloids were identified in a retrospective review. Patients who underwent the 5-FU/steroid combination with excision had a 92% average reduction in lesion size compared with 73% in the group of patients who did not receive 5-FU. Patients who received 5-FU/steroid without excision had an average lesion size reduction of 81%. Differences in complication rates were not statistically significant. Combination 5-FU/triamcinolone is superior to intralesional steroid therapy in the treatment of keloids.

1 November 2007 in Plastic and Reconstructive Surgery
Verified
Journal Article
Closed access
SDSteven P. M.D. Davison
Steven P. M.D. Davison
AMAli N. Mesbahi
Ali N. Mesbahi
IDIvica M.D. Ducic
Ivica M.D. Ducic
MSMarc Sarcia
Marc Sarcia
JDJoseph Dayan
Joseph Dayan
SSScott L. Spear
Scott L. Spear
Background: The inferior pedicle technique remains one of the most commonly used techniques in breast reduction surgery, despite lengthy operating times, poor nipple sensation, and bottoming-out over time. The superomedial pedicle in reduction mammaplasty has previously been described using limited incision patterns. This study evaluated the safety and reliability of the superomedial pedicle with various skin reduction patterns and compared the surgical time with the inferior pedicle technique. Methods: A total of 279 superomedial breast reductions were reviewed over a 6-year period, representing the transition period from inferior pedicle to superomedial pedicle techniques of three attending surgeons. Among these reductions, 215 had complete records and were included in the data analysis. The remaining 64 records were evaluated for viability of the nipple-areola complex. Assessments included skin pattern markings, average size of reduction, average body mass index, and complications. Risk factors and patient comorbidities were also recorded. Results: There were no cases of nipple loss in the series. The overall complication rate was 18 percent; patients' average body mass index was 29. The revision rate for contour or scar improvement was 4 percent. A statistically significant reduction in operating time of 41 minutes (p = 0.0001) was seen in comparison with the inferior pedicle reduction. Conclusions: The superomedial dermoglandular pedicle is a safe and reliable technique for reduction mammaplasty. Its versatility allows for reproducible results in a broad range of patients with various skin excision patterns. Use of the superomedial pedicle provides consistent results with respect to breast contour, nipple viability, and lasting superomedial fullness, and saves operating time compared with the inferior pedicle technique.